Chinook Therapeutics Stock Cash And Equivalents
| KDNYDelisted Stock | USD 39.25 0.20 0.51% |
Chinook Therapeutics fundamentals help investors to digest information that contributes to Chinook Therapeutics' financial success or failures. It also enables traders to predict the movement of Chinook Stock. The fundamental analysis module provides a way to measure Chinook Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Chinook Therapeutics stock.
Chinook |
Chinook Therapeutics Company Cash And Equivalents Analysis
Chinook Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Chinook Therapeutics Cash And Equivalents | 362.61 M |
Most of Chinook Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Chinook Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Chinook Therapeutics has 362.61 M in Cash And Equivalents. This is 55.83% lower than that of the Biotechnology sector and 18.9% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 86.58% higher than that of the company.
Chinook Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chinook Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Chinook Therapeutics could also be used in its relative valuation, which is a method of valuing Chinook Therapeutics by comparing valuation metrics of similar companies.Chinook Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Chinook Fundamentals
| Return On Equity | -0.57 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (39.98) % | |||
| Current Valuation | 2.64 B | |||
| Shares Outstanding | 67.05 M | |||
| Shares Owned By Insiders | 2.19 % | |||
| Shares Owned By Institutions | 96.71 % | |||
| Number Of Shares Shorted | 2.88 M | |||
| Price To Book | 3.06 X | |||
| Price To Sales | 27.90 X | |||
| Revenue | 6.13 M | |||
| Gross Profit | (135.08 M) | |||
| EBITDA | (164.2 M) | |||
| Net Income | (187.87 M) | |||
| Cash And Equivalents | 362.61 M | |||
| Cash Per Share | 5.76 X | |||
| Total Debt | 39.44 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 12.60 X | |||
| Book Value Per Share | 5.32 X | |||
| Cash Flow From Operations | (117.48 M) | |||
| Short Ratio | 3.43 X | |||
| Earnings Per Share | (3.24) X | |||
| Price To Earnings To Growth | (0.99) X | |||
| Target Price | 40.3 | |||
| Number Of Employees | 214 | |||
| Beta | 0.67 | |||
| Market Capitalization | 2.71 B | |||
| Total Asset | 574.08 M | |||
| Retained Earnings | (419.63 M) | |||
| Working Capital | 334.76 M | |||
| Z Score | 39.94 | |||
| Net Asset | 574.08 M |
About Chinook Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chinook Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chinook Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chinook Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Chinook Stock
If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |